TEL AVIV, Israel, October 13, 2014 /PRNewswire/ --
BioLight Life Sciences Investments Ltd.(TASE: BOLT)(OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that Ronen Castro, CEO of its subsidiary IOPtima Ltd., will present at the OIS@AAO (Ophthalmology Innovation Summit @ the American Academy of Ophthalmology) on Thursday, October 16, 2014, at 10:55 a.m. at the Palmer House Hilton in Chicago, IL.
The IOPtiMate™ system uses CO2 laser technology to perform a unique filtration surgery that treats glaucoma without penetrating the inner part of the eyeball. This innovation reduces post-operative complications and the use of eye drops compared with alternatives.
About BioLight
BioLight Life Sciences Investments invests in, manages and commercializes biomedical innovations grouped around defined medical conditions - ophthalmology and cancer diagnostics. The ophthalmic technologies include IOPtiMate™, a laser-based non-invasive surgical treatment for glaucoma; TeaRx, a point-of-care multi-parameter diagnostic test for dry-eye syndrome; and Eye-D®, a controlled release drug-delivery insert platform. The cancer diagnostic activities include tests that are designated for bladder, cervical, multiple myeloma and other cancers.
Leading key investors, holding about 45% of BioLight’s shares, are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals, India’s largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel.
For more information please visit the Company’s website at http://www.bio-light.co.il.
CONTACTS:
BioLight
Itai Bar-Natan, CFO
itai@bio-light.co.il
Tel: +972-73-2753400
SOURCE BioLight Life Sciences Investments Ltd
PR Newswire
October 13, 2014 - 9:00 AM EDT
Help employers find you! Check out all the jobs and post your resume.
